LNCAP/AR and a LnCAP/AR subline (LREX') with acquired resistance to 2nd generation antiandrogens

ChEBI2013-12-27 更新2026-07-21 收录

耐药性前列腺癌

抗雄激素药物研究

数据链接：

https://www.ebi.ac.uk/biostudies/ArrayExpress/studies/E-GEOD-51873 数据链接链接失效反馈

官方服务：

资源简介：

LNCAP/AR and a LnCAP/AR subline (LREX') with acquired resistance to 2nd generation antiandrogens

创建时间：

2013-12-27

GREB1 amplifies androgen receptor output in prostate cancer and contributes to antiandrogen resistance. GREB1 amplifies androgen receptor output in prostate cancer and contributes to antiandrogen resistance

耐药性前列腺癌

雄激素受体信号

Genomic amplification of the androgen receptor (AR) is an established mechanism of antiandrogen resistance in prostate cancer. Here we show that the magnitude of AR signaling output, independent of AR

NIAID Data Ecosystem70

Expression data from prostate cancer cell lines C4-2B (enzalutamide sensitive) and C4-2B-MDVR (enzalutamide resistant) cells. Homo sapiens

耐药性前列腺癌

差异基因表达分析

Prostate cancer C4-2B cells were cultured in enzalutamide in a dose-escalation manner. After sixty passages cells were resistant to enzalutamide, with a specific sets of genes been deregulated. We per

NIAID Data Ecosystem50

File S5 from Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer

肿瘤基因组学

耐药性前列腺癌

The table representing the top somatic mutations validated in the COSMIC database were compared between baseline sensitive (N=5) and resistant CTC-DNA (N=5).

NIAID Data Ecosystem40

Drug-induced epigenomic plasticity reprograms circadian rhythm regulation to drive prostate cancer towards androgen-independence [Cell line ChIP-Seq]

耐药性前列腺癌

昼夜节律表观遗传调控

In prostate cancer, androgen receptor (AR)-targeting agents are very effective in various stages of the disease. However, therapy resistance inevitably occurs and little is known about how tumor cells

NIAID Data Ecosystem70

RB-N phosphorylation promotes BRD4-mediated CREB signaling hyperactivation and BET inhibitor resistance

耐药性前列腺癌

靶向治疗联合方案

The combination of CREB inhibitor and JQ1 could overcome the resistance to BET inhibitors in RB loss prostate cancer. Our study firstly showed that GNB1L-CREB pathway was activated after RB loss and c

NIAID Data Ecosystem40

LNCAP/AR and a LnCAP/AR subline (LREX') with acquired resistance to 2nd generation antiandrogens

资源简介：

相关数据集